334 related articles for article (PubMed ID: 36001576)
1. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
[TBL] [Abstract][Full Text] [Related]
2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.
Conroy GM; Bauer SR; Pallotta AM; Duggal A; Wang L; Sacha GL
Pharmacotherapy; 2024 Jan; 44(1):28-38. PubMed ID: 37593883
[TBL] [Abstract][Full Text] [Related]
4. Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure.
Gavriilidis E; Antoniadou C; Chrysanthopoulou A; Ntinopoulou M; Smyrlis A; Fotiadou I; Zioga N; Kogias D; Natsi AM; Pelekoudas C; Satiridou E; Bakola SA; Papagoras C; Mitroulis I; Peichamperis P; Mikroulis D; Papadopoulos V; Skendros P; Ritis K
Clin Immunol; 2022 May; 238():109016. PubMed ID: 35447311
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
Ohsfeldt R; Kelton K; Klein T; Belger M; Mc Collam PL; Spiro T; Burge R; Ahuja N
Clin Ther; 2021 Nov; 43(11):1877-1893.e4. PubMed ID: 34732289
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab Versus Baricitinib for the Treatment of COVID-19 in Patients With Obesity.
Troyer BS; Kovacic Scherrer N; Garavaglia J
J Pharm Pract; 2024 Jun; 37(3):632-636. PubMed ID: 36803310
[No Abstract] [Full Text] [Related]
7. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
8. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
Kojima Y; Nakakubo S; Takei N; Kamada K; Yamashita Y; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454352
[No Abstract] [Full Text] [Related]
9. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
Paules CI; Wang J; Tomashek KM; Bonnett T; Singh K; Marconi VC; Davey RT; Lye DC; Dodd LE; Yang OO; Benson CA; Deye GA; Doernberg SB; Hynes NA; Grossberg R; Wolfe CR; Nayak SU; Short WR; Voell J; Potter GE; Rapaka RR
Ann Intern Med; 2024 Mar; 177(3):343-352. PubMed ID: 38408357
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group
Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
Hoang TN; Pino M; Boddapati AK; Viox EG; Starke CE; Upadhyay AA; Gumber S; Nekorchuk M; Busman-Sahay K; Strongin Z; Harper JL; Tharp GK; Pellegrini KL; Kirejczyk S; Zandi K; Tao S; Horton TR; Beagle EN; Mahar EA; Lee MYH; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Delmas OM; Wang S; Cooney KA; Sayegh MN; Wang L; Filev PD; Weiskopf D; Silvestri G; Waggoner J; Piantadosi A; Kasturi SP; Al-Shakhshir H; Ribeiro SP; Sekaly RP; Levit RD; Estes JD; Vanderford TH; Schinazi RF; Bosinger SE; Paiardini M
Cell; 2021 Jan; 184(2):460-475.e21. PubMed ID: 33278358
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
Asai S; Takahashi N; Kobayakawa T; Kaneko A; Watanabe T; Kato T; Nishiume T; Ishikawa H; Yoshioka Y; Kanayama Y; Watanabe T; Hirano Y; Hanabayashi M; Yabe Y; Yokota Y; Suzuki M; Terabe K; Ishiguro N; Imagama S; Kojima T
Clin Rheumatol; 2021 Aug; 40(8):3143-3151. PubMed ID: 34136969
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.
Cherian JJ; Eerike M; Bagepally BS; Das S; Panda S
Front Pharmacol; 2022; 13():1004308. PubMed ID: 36330085
[No Abstract] [Full Text] [Related]
17. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19.
Masiá M; Padilla S; García JA; García-Abellán J; Navarro A; Guillén L; Telenti G; Mascarell P; Botella Á; Gutiérrez F
Front Med (Lausanne); 2021; 8():749657. PubMed ID: 34820393
[No Abstract] [Full Text] [Related]
19. Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib-a biological or synthetic target specific) in patients hospitalized with COVID-19.
Barbosa AN; Silvinato A; Bacha H; Floriano I; Tanni S; Bernardo W
Rev Assoc Med Bras (1992); 2022 Jan; 68(1):3-8. PubMed ID: 35239928
[No Abstract] [Full Text] [Related]
20. Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study.
Avdeev SN; Trushenko NV; Tsareva NA; Yaroshetskiy AI; Merzhoeva ZM; Nuralieva GS; Nekludova GV; Chikina SY; Gneusheva TY; Suvorova OA; Shmidt AE
Cytokine; 2021 Oct; 146():155627. PubMed ID: 34237556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
